A note from Debra

Prosensa Update About Drisapersen & Other Programs Webinar

Posted on September 22, 2014 9:24 pm

UPPMD is hosting a Prosensa Update About Drisapersen & Other Programs webinar on behalf of all of its member organizations worldwide.


Date and Time:  Thursday October 2nd 2014 at 6pm CET (noon Eastern and 9 a.m. Pacific)


The webinar will be presented by Anthony Hall MD, Medical Director Medical Affairs of Prosensa and he will be joined by the following guest speakers:

-          Annemieke Aartsma-Rus PhD, Associate Professor at the Department of Human Genetics at Leiden University Medical Center (the Netherlands) and Visiting Professor at the Institute of Genetic Medicine of Newcastle University (UK).

-          Thomas Voit MD, Professor of Pediatrics at the University Pierre et Marie Curie Paris 6, Medical and Scientific Director of the Institute of Myology at the Pitié-Salpêtrière Hospital and Director of the mixed UPMC-INSERM-CNRS research unit UM76 (France).

-          Brenda Wong MD MBBS, Professor of Clinical Pediatrics and Neurology and Director of Comprehensive Neuromuscular Center at Cincinnati Children’s Hospital Medical Center and Associate Professor at University of Cincinnati Department of Pediatrics (US).


To participate:
1.     Visit ReadyTalk.com<http://www.readytalk.com/> and use participant code 9449985. (Be sure to test your computer beforehand<https://core.readytalk.com/interface/participantTest.jsp?host=readytalk>)
2.     Audio Dial-In Information:
•  U.S. & Canada: Dial 866.740.1260 and use the Access Code 9449985
•  Outside the U.S. and Canada: Lookup your number<


Your questions:

Questions for Prosensa to be addressed during this webinar can be sent till September 29th 2014 to UPPMD@euronet.nl 


Prosensa announces commencement of re-dosing of drisapersen in North America in patients with Duchenne muscular dystrophy

Posted on September 17, 20147:27 pm

CureDuchenne is delighted to share that Prosensa has begun re-dosing patients. See below for today’s announcement.  We are happy that CureDuchenne funding is helping to move Prosensa’s exon skipping programs forward. Our $7 million collaboration with Prosensa is helping to accelerate access to exon skipping drugs for several mutations for patients who so desperately need it. Read more »

Duchenne Research and Physical Therapy Update – Parent Sessions

Posted on September 15, 20144:48 pm

  CureDuchenne and the Duchenne Therapy Network are pleased to announce two upcoming parent education sessions featuring a Duchenne research and physical therapy update on September 27 in San Jose, Calif., and on October 17 in Mesa, Arizona.  CureDuchenne Chief Scientific Officer Dr. Mike Kelly will present the most current updates on Duchenne muscular dystrophy Read more »